Abstract
Saxagliptin is a potent, selective, reversible dipeptidyl peptidase 4 (DPP4) inhibitor specifically designed for extended inhibition of the DPP4 enzyme and is currently under development for the treatment of type-2 diabetes. The pharmacokinetics of saxagliptin were evaluated in rats, dogs, and monkeys and used to predict its human pharmacokinetics. Saxagliptin was rapidly absorbed and had good bioavailability (50–75%) in the species tested. The plasma clearance of saxagliptin was higher in rats (115 ml/min/kg) than in dogs (9.3 ml/min/kg) and monkeys (14.5 ml/min/kg) and was predicted to be low to moderate in humans. The plasma elimination half-life was between 2.1 and 4.4 h in rats, dogs, and monkeys, and both metabolism and renal excretion contributed to the overall elimination. The primary metabolic clearance pathway involved the formation of a significant circulating, pharmacologically active hydroxylated metabolite, M2. The volume of distribution values observed in rats, dogs, and monkeys (1.3–5.2 l/kg) and predicted for humans (2.7 l/kg) were greater than those for total body water, indicating extravascular distribution. The in vitro serum protein binding was low (≤30%) in rats, dogs, monkeys, and humans. After intra-arterial administration of saxagliptin to Sprague-Dawley and Zucker diabetic fatty rats, higher levels of saxagliptin and M2 were observed in the intestine (a proposed major site of drug action) relative to that in plasma. Saxagliptin has prolonged pharmacodynamic properties relative to its plasma pharmacokinetic profile, presumably due to additional contributions from M2, distribution of saxagliptin and M2 to the intestinal tissue, and prolonged dissociation of both saxagliptin and M2 from DPP4.
Footnotes
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.108.026088.
-
ABBREVIATIONS: DPP4, dipeptidyl peptidase 4; BMS-477118, (S)-3-hydroxyadamantylglycine-l-cis-4,5-methanoprolinenitrile, saxagliptin; BMS-510849, (S)-3,5-dihydroxyadamantylglycine-l-cis-4,5-methanoprolinenitrile, metabolite M2; SD, Sprague-Dawley; ZDF, Zucker diabetic fatty; LC-MS/MS, liquid chromatography-tandem mass spectrometry; BDC; bile duct-cannulated; SAD, single ascending dose; SIT, species invariant time; ROE, rule of exponent.
-
↵1 Current affiliation: SV Life Sciences LLC, Foster City, California.
-
↵2 Current affiliation: Duck Flats Pharma, Elbridge, New York.
-
↵3 Current affiliation: Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
- Received December 8, 2008.
- Accepted February 26, 2009.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|